MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

MDT

86.73

-1.87%↓

120.12

-0.54%↓

VEEV

166.25

+4.78%↑

HQY

83.3

+3.65%↑

NEOG

9.45

0%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

3.18 -2.45

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.04

Максимум

3.24

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+541.03% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-100M 288M
Предишно отваряне	5.63
Предишно затваряне	3.18

Настроения в новините

By Acuity

75%

25%

325 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.04.2026 г., 23:36 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14.04.2026 г., 23:24 ч. UTC

Горещи акции

Stocks to Watch: Gloo, Broadcom, GitLab

14.04.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14.04.2026 г., 21:32 ч. UTC

Значими двигатели на пазара

GitLab Shares Rise on Expanded Google Cloud Collaboration

14.04.2026 г., 23:54 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Technical Correction -- Market Talk

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14.04.2026 г., 22:54 ч. UTC

Печалби

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14.04.2026 г., 22:17 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14.04.2026 г., 22:16 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14.04.2026 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14.04.2026 г., 22:14 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14.04.2026 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14.04.2026 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14.04.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

14.04.2026 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 20:32 ч. UTC

Горещи акции

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14.04.2026 г., 19:59 ч. UTC

Придобивния, сливания и поглъщания

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14.04.2026 г., 19:38 ч. UTC

Печалби

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14.04.2026 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14.04.2026 г., 19:21 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14.04.2026 г., 19:09 ч. UTC

Придобивния, сливания и поглъщания

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

14.04.2026 г., 18:30 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

541.03% нагоре

12-месечна прогноза

Среден 20 USD 541.03%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

325 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.